Squarepoint
ORIC icon

Squarepoint’s Oric Pharmaceuticals ORIC Stock Holding History

Squarepoint’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-229,383
Closed -$1.88M – 4769
2025
Q4 		$1.88M Buy
229,383
+198,650
+646% +$2.29M ﹤0.01% 2112
2025
Q3 		$369K Sell
30,733
-76,034
-71% -$800K ﹤0.01% 3504
2025
Q2 		$1.08M Buy
+106,767
New +$717K ﹤0.01% 2598
2024
Q4 		– Sell
-16,666
Closed -$171K – 5381
2024
Q3 		$171K Sell
16,666
-17,318
-51% -$171K ﹤0.01% 3743
2024
Q2 		$240K Buy
33,984
+16,613
+96% +$149K ﹤0.01% 3556
2024
Q1 		$239K Sell
17,371
-8,685
-33% -$103K ﹤0.01% 3525
2023
Q4 		$240K Buy
+26,056
New +$188K ﹤0.01% 3489
2023
Q2 		– Sell
-37,400
Closed -$213K – 3881
2023
Q1 		$213K Buy
+37,400
New +$195K ﹤0.01% 2769
2022
Q3 		– Sell
-59,073
Closed -$265K – 3308
2022
Q2 		$265K Buy
59,073
+45,293
+329% +$181K ﹤0.01% 2349
2022
Q1 		$74K Buy
+13,780
New +$124K ﹤0.01% 2646
2021
Q2 		– Sell
-10,342
Closed -$253K – 3573
2021
Q1 		$253K Buy
+10,342
New +$327K ﹤0.01% 2535

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Squarepoint's ORIC Position: Q1 2026 in Review

Squarepoint sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 229,383 shares — an estimated $1.88M sold.

Squarepoint first reported a position in ORIC in Q1 2021 and held it in 11 quarters. The position peaked at $1.88M in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Squarepoint reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 229,383 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
  • Squarepoint first reported a position in Oric Pharmaceuticals in Q1 2021 and held it in 11 quarters.
  • Squarepoint's Oric Pharmaceuticals position peaked at $1.88M in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.